Tresiba at Work and in Daily Life: A Women's Guide to Insulin Degludec

What Makes Tresiba Different From Other Basal Insulins

Tresiba works differently from NPH, glargine U-100, or detemir, and understanding that difference is what makes living with it feel manageable rather than rigid.

After you inject insulin degludec, the molecules form long, stable chains under your skin. Those chains dissolve slowly and steadily, releasing insulin into your bloodstream at a flat, predictable rate for up to 42 hours. The clinical effect is a duration of action exceeding 42 hours with a coefficient of variation for glucose-lowering effect that is four times lower than insulin glargine U-100, meaning day-to-day fluctuation in how hard Tresiba works is much smaller.

Why the Flat Profile Matters for Women

Women's glucose levels do not stay flat. Your menstrual cycle, stress hormones, shift-work sleep disruption, and perimenopause-related estrogen swings all push blood sugar up and down on top of whatever your basal insulin is doing. A basal insulin with its own variability compounds the problem. Tresiba's flat action curve gives you one less variable to manage.

The BEGIN trials program, a series of Phase 3 trials comparing insulin degludec to insulin glargine, found that degludec produced significantly lower rates of nocturnal hypoglycemia in both type 1 and type 2 diabetes. Nocturnal lows are particularly new for women who are pregnant, breastfeeding, or managing children overnight, so this difference has real practical weight.

Approved Doses and Strengths

Tresiba comes in two concentrations:

• U-100 (100 units per mL), for most adults and all children
• U-200 (200 units per mL), for adults requiring more than 20 units per day; same pen volume, twice the dose per unit marking

The starting dose for insulin-naive adults with type 2 diabetes is typically 10 units once daily, titrated upward based on fasting glucose targets. For type 1 diabetes, the starting dose is calculated as a percentage of your total daily insulin requirement, usually around one-third to one-half.

Tresiba at Work: Practical Scheduling Across Different Jobs

The most common workplace concern women raise about basal insulin is timing. Shift workers, nurses, teachers, flight attendants, and anyone with irregular hours have historically struggled with basal insulins that required strict 24-hour dosing windows.

Tresiba's labeling explicitly permits a dosing window. The FDA-approved prescribing information states that Tresiba can be administered at any time of day, with the main instruction being that at least 8 hours must pass between doses. This is not a loophole. It is a pharmacologically grounded flexibility built on the drug's 25-hour half-life.

Shift Workers and Rotating Schedules

If your shift rotates between days and nights, here is a workable approach that clinicians use in practice:

1. Pick an anchor time that falls within every shift (for example, 7 AM works whether you work days or nights, because you are awake before or after a day shift and returning home after a night shift).
2. Allow yourself up to 8 hours on either side of that anchor on unusually early or late days.
3. Never dose twice within an 8-hour window, even if you forget and realize late.

A 2014 crossover study published in Diabetes Care confirmed that intentional 8-hour dose-time shifts with insulin degludec produced no clinically meaningful difference in HbA1c or hypoglycemia rates compared to fixed daily dosing. That evidence directly supports flexible scheduling in practice.

Office and Clinic Settings

Injecting at work is legal, protected, and normal. In the United States, the Americans with Disabilities Act requires employers to provide reasonable accommodations for diabetes management, which includes a private space to inject and time to test blood glucose. You do not need to inject in a bathroom.

Tresiba's 56-day room-temperature stability means you can keep a pen in your desk drawer or bag without a cold pack for the entire month. That removes one of the logistical burdens of workplace insulin storage.

Travel and Time Zones

Crossing time zones with Tresiba is simpler than with older basal insulins. The general guidance from diabetes specialists: if you cross fewer than 4 time zones, inject at your usual local time without adjustment. For longer east-west or west-east travel, shift your injection time gradually by 1 to 2 hours per day in the direction of travel, staying within the 8-hour window throughout. The ACOG guidance on diabetes management during travel does not specifically address insulin degludec, but the flexibility principle holds for non-pregnant women with type 1 or 2 diabetes.

How Your Hormones Change Your Tresiba Dose

This section covers what most general diabetes resources skip: the sex-specific physiology that changes how much insulin you need across your reproductive life.

The Menstrual Cycle and Insulin Resistance

Progesterone is an insulin antagonist. In the luteal phase (roughly days 15 to 28 of a typical cycle), rising progesterone increases insulin resistance. Many women with type 1 diabetes notice fasting glucose climbing in the week before their period, requiring a temporary basal increase of 10 to 20 percent in the luteal phase.

A 2017 study in Diabetes Care tracked continuous glucose monitor data across menstrual cycles in women with type 1 diabetes. Researchers found statistically significant increases in time above range during the late luteal phase compared to the follicular phase. Insulin requirements then drop sharply with menstruation, so overshooting basal correction at that point risks hypoglycemia.

Tracking your cycle alongside your glucose data for two or three months gives you a pattern you and your clinician can use to build a proactive titration schedule, rather than reacting to unexplained highs each month.

PCOS and Insulin Degludec

Polycystic ovary syndrome (PCOS) affects 6 to 13 percent of women of reproductive age and carries a substantially elevated risk of type 2 diabetes. Women with PCOS who develop type 2 diabetes and require basal insulin may find that their insulin resistance is more severe and less predictable than in women without PCOS, partly because androgen levels and ovulatory irregularity affect glucose metabolism in ways that standard titration algorithms do not account for.

There are no published trials of insulin degludec specifically in women with PCOS and type 2 diabetes. This is an evidence gap. Extrapolating from general type 2 data is reasonable, but your dose titration may need to happen more slowly and with closer follow-up.

Perimenopause and Menopause

Estrogen has a glucose-lowering effect. As estrogen levels fall and fluctuate in perimenopause, many women with diabetes experience new glycemic instability that looks like insulin resistance one week and increased hypoglycemia risk the next.

A practical framework for perimenopausal women on Tresiba: treat perimenopause as a period of monthly re-titration rather than a stable state. Download your continuous glucose monitor or meter data every 4 weeks. Look for patterns tied to vasomotor symptom clusters (hot flashes and night sweats tend to cluster around estrogen troughs, which may also correlate with glucose dips). Adjust your basal by no more than 2 units at a time, with a minimum of 3 days between adjustments. Hormone therapy can stabilize glucose variability for some women, and The Menopause Society's 2023 position statement on hormone therapy notes that systemic estrogen therapy may improve insulin sensitivity in postmenopausal women, which could require a downward dose adjustment in your Tresiba.

After menopause, insulin requirements often stabilize but at a different level than during reproductive years. Women who were managing well on a given basal dose in their 40s may find they need less (improved sensitivity with stable estrogen absence) or more (weight gain, decreased activity, metabolic aging) in their 50s and 60s.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, planning pregnancy, or not using reliable contraception while on any insulin.

Pregnancy Safety

Insulin degludec carries FDA Pregnancy Category B status, based on animal reproduction studies showing no harm and limited human data. Insulin does not cross the placenta in meaningful amounts; the concern with insulin therapy in pregnancy is not fetal drug exposure but rather the risk of maternal hypoglycemia and the consequences of poor glycemic control on fetal development.

ACOG Practice Bulletin 201 recommends that women with pregestational diabetes maintain preprandial glucose levels of 70 to 95 mg/dL and postprandial levels below 120 mg/dL at 2 hours. Achieving those targets during pregnancy typically requires more frequent dose adjustments than outside of pregnancy, because insulin resistance increases substantially, particularly in the second and third trimesters.

NPH and insulin detemir have larger safety datasets in pregnancy than degludec. Insulin glargine U-100 also has more published human pregnancy data. Tresiba is not the first-line choice for most clinicians managing pregestational or gestational diabetes, but it is sometimes continued in women who were well-controlled on it before conception, under close monitoring. A 2019 randomized trial (EXPECT) compared insulin degludec to insulin detemir in type 1 diabetes during pregnancy and found no significant difference in maternal or neonatal outcomes, though the trial was underpowered for rare adverse events.

If you are not planning pregnancy, use reliable contraception. This applies to all women of reproductive age with diabetes who are on any insulin regimen, because unplanned pregnancy with poor glycemic control in the first trimester carries meaningful risk of congenital anomalies.

Lactation

Insulin degludec is a large protein molecule. Large proteins are generally degraded in the infant's gastrointestinal tract even if they transfer into breast milk, making systemic infant exposure unlikely. The NIH LactMed database classifies insulin as acceptable during breastfeeding.

One practical note: breastfeeding lowers blood glucose in women with diabetes. You may need to reduce your Tresiba dose or eat a small snack before or during nursing sessions to avoid hypoglycemia. This effect is most pronounced in the first weeks postpartum and often diminishes as milk supply stabilizes. Track your glucose around feeding sessions for the first 4 to 6 weeks.

Postpartum

Insulin resistance drops dramatically after delivery. Women who required high basal doses during the third trimester often need 30 to 50 percent less insulin in the first 48 to 72 hours postpartum. Your diabetes care team should reassess your Tresiba dose within 24 hours of delivery. If you are returning to work while breastfeeding, bring glucose supplies, fast-acting carbohydrates, and your Tresiba pen, because pumping sessions can drop your glucose just as feeding sessions do.

Who This Regimen Is Right For, and Who Should Look Elsewhere

Not every woman with diabetes is the best candidate for Tresiba. Here is an honest breakdown by life stage and condition.

Good Candidates

• Women with type 1 or type 2 diabetes who have irregular schedules, shift work, or frequent travel
• Women who have experienced nocturnal hypoglycemia on NPH or glargine U-100 and want a flatter action profile
• Women who are post-menopausal and want a stable basal that requires infrequent titration during a period of relative hormonal stability
• Women with type 2 diabetes who are insulin-naive and starting basal therapy for the first time (simple once-daily regimen)

Women Who Should Discuss Alternatives

• Women who are pregnant or planning pregnancy in the near term (detemir has more published pregnancy data and is often preferred)
• Women who are in very early perimenopause with wildly fluctuating glucose, who may benefit from a shorter-acting basal that can be split into twice-daily dosing for more flexibility
• Women with a history of recurrent severe hypoglycemia who require extremely careful titration (while Tresiba's flat profile reduces hypoglycemia risk, very low starting doses and slow titration matter)
• Women with significant renal impairment, where all insulin doses require more frequent monitoring and adjustment

Hypoglycemia Risk in Women: What the Data Actually Shows

Women have a different hypoglycemia risk profile than men. Physiologically, women have a blunted glucagon response to low blood sugar, meaning the body's automatic recovery mechanism is less effective. A 2015 analysis in Diabetes Care found that women with type 1 diabetes reported more frequent severe hypoglycemic episodes than men, and more episodes occurring during sleep.

Tresiba's flat profile specifically reduces nocturnal hypoglycemia. The SWITCH 1 trial, a crossover study in type 1 diabetes, found a 30 percent reduction in overall symptomatic hypoglycemia and a 42 percent reduction in nocturnal confirmed hypoglycemia (<56 mg/dL) when patients switched from glargine U-100 to degludec. Sex-disaggregated data from SWITCH 1 were not published separately, which is an evidence gap.

For women who are at highest risk, specifically those who are pregnant, postpartum and breastfeeding, or perimenopausal with unpredictable hormonal swings, continuous glucose monitoring (CGM) paired with Tresiba offers the best combination of protection. CGM alarms can catch falling glucose before it becomes symptomatic hypoglycemia.

Storage, Disposal, and Workplace Logistics

Temperature: Unused Tresiba pens should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). Once in use, a pen can be stored at room temperature (up to 86°F / 30°C) for up to 56 days. This is longer than glargine U-100 (28 days) or detemir (42 days).

At work: Keep your in-use pen in a desk drawer, locker, or insulated pouch. Do not leave it in a car where summer heat can exceed 86°F / 30°C. Many women clip a temperature-indicating sticker to the pen cap to confirm the pen has stayed within range, particularly during travel.

Needle disposal: Sharps containers are available as small portable versions (roughly the size of a travel mug) that fit in a tote bag or work bag. Federal law (and most state laws) prohibit disposing of needles in regular trash. Check your state's regulations at the FDA's safe sharps disposal page.

Dose pen function: The Tresiba FlexTouch pen doses in 1-unit increments for U-100 and 2-unit increments for U-200. The push-button requires less force than many other pen devices, which matters for women with hand or wrist conditions (rheumatoid arthritis, carpal tunnel syndrome). Check that the dose window shows a clear number and always perform an airshot before the first injection from each new pen.

Titrating Your Dose: A Step-by-Step Approach for Women

Titrating Tresiba is not the same as titrating a shorter-acting basal. Because of its long half-life, full steady-state is not reached for 3 to 4 days after any dose change. Adjusting more frequently than that means you are reacting to a dose that has not yet reached its full effect.

A conservative titration schedule for women:

1. Establish your fasting glucose target with your clinician. For most non-pregnant adults, this is 80 to 130 mg/dL per ADA Standards of Care 2024.
2. Check fasting glucose each morning before eating. Use the average of three consecutive mornings, not a single reading.
3. Adjust by 2 units (not more) if the 3-day average is above target. Wait 3 to 4 days before the next adjustment.
4. Do not adjust up if you had any hypoglycemia in the previous 3 days. Identify and address the cause first.
5. Note where you are in your menstrual cycle. If your fasting glucose is running high in the luteal phase, consider a temporary 2-unit increase that you reverse with menses rather than a permanent dose change.

The ADA Standards of Care 2024 note that basal insulin titration algorithms are most effective when patients have clear written instructions and a defined contact method for questions, rather than waiting for the next scheduled appointment.

A Note on Evidence Gaps for Women

The major Tresiba trials (BEGIN, SWITCH) enrolled both sexes, but published results were rarely broken down by sex. Sex-disaggregated data on insulin degludec's pharmacokinetics in women at different hormonal stages are thin. There are no published trials of Tresiba specifically in women with PCOS, or in perimenopausal women as a defined subgroup. The EXPECT trial in pregnancy provides some reassurance but was underpowered. This is not unusual for diabetes research, which has historically treated male physiology as the default and female hormonal variation as noise.

What this means for you in practice: your experience on Tresiba may not perfectly match the average trial result, especially around your cycle or during perimenopause. Keeping detailed glucose records linked to your hormonal status is not just useful for your clinician. It is the kind of n-of-1 data that fills in where published literature leaves off.